Sonoma Pharmaceuticals In... (SNOA)
| Bid | 3.47 |
| Market Cap | 5.66M |
| Revenue (ttm) | 13.97M |
| Net Income (ttm) | -3.75M |
| EPS (ttm) | -2.26 |
| PE Ratio (ttm) | -1.55 |
| Forward PE | -2.15 |
| Analyst | n/a |
| Ask | 3.58 |
| Volume | 92,941 |
| Avg. Volume (20D) | 2,701,688 |
| Open | 3.79 |
| Previous Close | 3.80 |
| Day's Range | 3.47 - 3.85 |
| 52-Week Range | 1.75 - 9.40 |
| Beta | 1.68 |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; ...
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · accessnewswire.com
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in OrlandoBOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoc...
2 months ago · accessnewswire.com
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial ResultsRevenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net lo...